Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
News Oct 03, 2013
Metamark Genetics, Inc. has announced that Cornelius J. Merlini, former general manager of HealthTronics Laboratory Solutions (HLS), has been appointed Metamark's Senior Vice President and Chief Commercial Officer.
In August 2013, Metamark acquired HLS, a national uropathology laboratory, from Endo Health Solutions, Inc. Mr. Merlini will report to Metamark President and Chief Executive Officer, Shawn M. Marcell, and will join the company's senior leadership team.
"We are pleased that Cornelius has joined Metamark. His exceptional leadership, commercial acumen, and track record bringing paradigm-changing products to market have produced transformational business growth," said Mr. Marcell.
Mr. Marcell continued, "Cornelius already is an established leader of Metamark's newly-acquired uropathology business, where he assembled a talented, dedicated team - including a specialized national field sales force. This commercial team nicely complements Metamark's innovative research and development efforts, and will accelerate the launch of ProMark™, our novel prostate cancer prognostic test."
"Metamark's strong science engine fits perfectly with its new commercial and operational machine," said Mr. Merlini. "ProMark™ could redefine the management of early stage prostate cancer and become a standard test sought by patients and ordered by urologists when making well-informed treatment decisions. It is exciting to join a company that could change the way prostate cancer is treated."
Mr. Merlini has over twenty-five years of life science experience across a wide array of functions and businesses.
Prior to HealthTronics Lab Solutions, Mr. Merlini was SVP, Commercial Operations at Cord Blood Registry, a market leader in cord blood stem cell banking.
He spent ten years with increasing marketing, management and franchise leadership responsibilities at Johnson & Johnson, where he served most recently as Worldwide Vice-President of the cardiovascular franchise for Johnson & Johnson's biopharmaceutical business.
Earlier, Mr. Merlini gained successful sales and sales leadership experience with Marion Laboratories (now Sanofi-Aventis).
New Blood Test Could Help Distinguish Heart Attack from Heart StrainNews
A new blood test developed by a UAlberta medical researcher is better at detecting damage to the heart caused by an actual heart attack. The test promises to improve how physicians diagnose and treat patients experiencing a possible heart attack.READ MORE
Rapid Test Helps with Administering the "Correct" DrugNews
In just three hours, a new rapid test will give information on which available antibiotic is still effective in a concrete case.READ MORE
‘Digistain’ Technology Offers Revolution in Detailed Cancer DiagnosisNews
New cutting edge technology can be used to grade cancer tumours, eradicating human subjectivity and ensuring patients get the right treatment.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018